Point72 (DIFC)’s Harvard Bioscience HBIO Stock Holding History

Point72 (DIFC)’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-243	Closed	-$6.92K	–	1621
2024 Q2	$6.92K	Buy	+243	New	+$8.52K	﹤0.01%	1348

Other funds holding HBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAIM

Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return

Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Point72 (DIFC)'s HBIO Position: Q3 2024 in Review

Point72 (DIFC) sold out of Harvard Bioscience (HBIO) in Q3 2024, closing a stake of 243 shares — an estimated $6.92K sold.

Point72 (DIFC) first reported a position in HBIO in Q2 2024 and held it in 1 quarter. The position peaked at $6.92K in Q2 2024. 94 funds tracked by Wall St. Rank hold HBIO as of Q3 2024.

Point72 (DIFC) reported no remaining Harvard Bioscience position as of Q3 2024 after selling out during the quarter.
Point72 (DIFC) sold 243 Harvard Bioscience shares in Q3 2024, an estimated $6.92K.
Point72 (DIFC) first reported a position in Harvard Bioscience in Q2 2024 and held it in 1 quarter.
Point72 (DIFC)'s Harvard Bioscience position peaked at $6.92K in Q2 2024.
94 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2024.

Based on Point72 (DIFC)'s 13F filing for Q3 2024, filed 14 Nov 2024.